Pfizer Rallies To Fix Tornado Damage At Key Injectables Plant

Amid Fears Of Shortages Due To Impact On Former Hospira Rocky Mount Facility

In the aftermath of tornado damage to Pfizer’s US Rocky Mount sterile injectables plant, the company has set out relief efforts while acknowledging the “critical role” the facility plays for the US healthcare system.

Tornado damage to Pfizer's Rocky Mount plant
Pfizer shared this image of the damage to the Rocky Mount plant • Source: Pfizer

When Pfizer’s US sterile injectables facility at Rocky Mount was hit by a tornado last week, initial concerns over the immediate safety of staff were soon followed by speculation over potential shortages and disruptions to product availability, given the significance of the plant to the US supply chain.

The former Hospira facility in North Carolina is one of the largest sterile injectables manufacturing sites in the world, producing around a quarter of Pfizer’s sterile injectables – representing nearly 8% of those used in US hospitals

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Business

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By 

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By 

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.